A Study of Elenestinib in Healthy Adult Female Participants

Part of paid clinical trials in Tempe, Arizona.

Sponsor
Blueprint Medicines Corporation
Study ID
NCT07388511
Phase
PHASE1
Status
Completed

Conditions

  • Healthy Participants

Eligibility Criteria

Sex
FEMALE
Age
18 Years - 65 Years
Healthy Volunteers
Accepted

Interventions

  • Elenestinib — DRUG
    Specified dose on specified days
  • Midazolam — DRUG
    Specified dose on specified days
  • Levonorgestrel/Ethinyl Estradiol — DRUG
    Specified dose on specified days

Study Details

The main objectives of this study are to determine the effect of elenestinib on the pharmacokinetic parameters (how the drug is absorbed, distributed, and processed by the body) of midazolam, and to determine the effect of elenestinib on the pharmacokinetic parameters of levonorgestrel/ethinyl estradiol, when given as a combined oral contraceptive. Healthy adult participants will receive midazolam and levonorgestrel/ethinyl estradiol with and without elenestinib and have blood samples taken.

Key Dates

Start date
Feb 5, 2026
Status verified
Apr 2026
Primary completion
Apr 2, 2026
Completion
Apr 2, 2026

Study Design

Enrollment
20 participants (actual)
Allocation
NA
Intervention model
SEQUENTIAL
Primary purpose
OTHER

Arms

  • Experimental: Elenestinib, Midazolam, and Levonorgestrel/Ethinyl Estradiol

Primary Outcome Measure

Area under the concentration-time curve, from time 0 to the last observed non-zero concentration (AUC0-t) [ Time Frame: Up to 27 days ]

Locations (1)

FacilityCityStateZIPSite coordinators
Celerion, IncTempeArizona85282-

Find similar trials in Tempe, AZ

By research site
Celerion, Inc· Tempe, AZ

Related Studies